Recent Finacing
Recent Raise
Cytovia develops off-the-shelf gene-edited iNK and CAR-iNK cells from iPSCs plus NK-engager multispecific antibodies, operates R&D in Natick and GMP in Puerto Rico, advancing GPC3-targeted HCC and China JV.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Cytovia Therapeutics.
